RxDoctor Payments Data

Michael Butera, MD

Infectious Disease · San Diego, CANPI 1104925205

Payments from drug & device makers

$17,944in general payments, 2019–2025

Across 151 payments — averaging $118.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$13K
  • AbbVie$3K
  • GSK$349
  • Gilead$255
  • Insmed, Inc.$252
  • Astellas Pharma US Inc$206
  • plus $901 from 15 others

What the payments were for

  • Speaking & faculty fees$14,55081%
  • Travel & lodging$1251%
  • Food & beverage$3,05417%
  • Education$2151%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,944 in reported general payments places this provider in the 80th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$155,884
Medicare patients
223
Services billed
1,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DescovyEmtricitabine/Tenofov Alafenam12$24,773
Posaconazole12$20,960
AbrysvoRsv Vacc, Pref A And Pref B/Pf39$11,754
Atazanavir Sulfate12$2,780
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,284
Ritonavir12$772
LantusInsulin Glargine,hum.Rec.Anlog11$692
Amoxicillin17$260
Rosuvastatin Calcium20$62
Atorvastatin Calcium11$59
Lovastatin15$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadDescovy$255$24,77312 claims
PfizerAbrysvo$90$11,75439 claims
GSKShingrix$349$2,28411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 856 infectious disease providers in California.

Other infectious disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →